No items found.
The last year 2018 was extremely successful for MultiplexDX. Therefore, it is unsurprising that the company was among the finalists for the EY Entrepreneur of The Year 2018 Awards in Slovakia. This highlights the first time a biotech company was nominated for this award in Slovakia.
Dr. Pavol Cekan (CEO) and Dr. Peter Kilian (COO) are young entrepreneurs, who have an extraordinary entrepreneurial story, underlined by an impressive transformation from scientists to businessmen. Their goal is to eliminate cancer misdiagnosis through bringing 100% accurate, quantitative and affordable diagnostic tests for oncological patients.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“It was a great honor to be among the nominees in the EY Entrepreneur Contest 2018. On one hand, it gives us prestige in the community of entrepreneurs; on the other, our story inspires others. Our ideas are pioneering, therefore we want to encourage other scientists “to come out of their shell” to build a biotech industry in Slovakia. Only science can accelerate growth and innovations to build a better country.”
EY Entrepreneur of The Year Nominees are judged by an independent panel composed of several distinguished business leaders in Slovakia and previous award recipients. There are 6 main criteria: 1. Entrepreneurship, 2. Innovation, 3. Integrity, 4. Finances, 5. Strategic Orientation, and 6. Global/Social Impact. The EY Entrepreneur of The Year contest has the patronage of the President of the Slovak Republic.
The EY Entrepreneur of The Year Awards is an award sponsored by Ernst & Young that celebrates the idea of entrepreneurship. The award was founded in 1986 in the U.S. The contest recognizes the most innovative and inspiring entrepreneurial leaders and is proclaimed to be the most prestigious contest for entrepreneurs in the world. The contest runs in more than 60 countries and each country winner gathers for the annual ceremony in Monte Carlo, where the EY World Entrepreneur of The Year is announced.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.